Arcadia Biosciences (RKDA) Director Amy Yoder Receives 10,000-Share Award

What happened Amy Yoder, a director of Arcadia Biosciences, was granted a derivative award reported as 10,000 shares/options on September 10, 2026. The Form 4 reports an acquisition price of $0.00 (derivative), so the reported immediate value is $0. This is a grant of equity-based compensation (not an open-market purchase or sale) and no shares were reported sold.

Key details

• Transaction date: 2026-09-10; filing date: 2026-09-14 (Form 4 appears timely).
• Transaction type/code: Award/Grant (A); reported acquisition price $0.00 for 10,000 shares (derivative).
• Shares owned after transaction: not disclosed in the provided filing details.
• Footnote: The option will become 100% vested and exercisable on the earlier of (i) September 10, 2027 or (ii) the issuer’s next Annual Meeting of Stockholders, subject to continued service.
• No indication of immediate sale or cashless exercise in this filing.

Context This is a typical director equity grant used as compensation and does not by itself indicate insider buying or selling behavior in the open market. Because it’s reported as a derivative option with a stated vesting schedule, its economic value to the insider depends on future vesting and any subsequent exercise and disposition.